可可黄烷醇补充剂与年龄相关性黄斑变性风险:COSMOS随机临床试验的辅助研究
这项COSMOS随机临床试验的预设辅助研究纳入21442名美国老年人,评估每日500毫克可可黄烷醇补充剂对年龄相关性黄斑变性(AMD)发生或进展的影响。中位随访3.6年,主要复合终点在可可提取物组与安慰剂组间无显著差异(HR 0.87,95%CI 0.71-1.08,P=0.21),但前2年治疗期间风险降低23%(HR 0.77,95%CI 0.59-1.01),2年后无额外获益(HR 1.06,95%CI 0.76-1.50)。
要点
- 每日500毫克可可黄烷醇补充剂对AMD总体发生风险无显著影响(HR 0.87,95%CI 0.71-1.08,P=0.21)。
- 治疗前2年可可提取物组AMD风险降低23%(HR 0.77,95%CI 0.59-1.01),2年后无额外获益(HR 1.06,95%CI 0.76-1.50)。
- 作者认为不能排除早期可能的适度治疗效果,需进一步研究明确可可提取物是否有助于降低AMD风险。
核心结论
- 在COSMOS随机临床试验的这项辅助研究中,中位3.6年的可可提取物补充对老年女性和男性AMD的总体发生无影响。
- 但不能排除试验早期可能的适度治疗效果,需进一步研究以明确可可提取物是否有助于降低AMD风险。
研究设计与样本
- COSMOS试验的预设辅助研究,采用双盲、安慰剂对照、2×2析因随机临床试验设计,评估可可提取物补充剂和多种维生素补充剂对心血管疾病和癌症的预防作用。
- 纳入21442名美国成年人,包括12666名65岁及以上女性和8776名60岁及以上男性。
- 干预阶段为2015年6月至2020年12月,数据分析于2024年8月完成。
- 干预措施为可可提取物补充剂(每日500毫克可可黄烷醇,含80毫克(-)-表儿茶素)或安慰剂。
- 主要终点为基线AMD患者中新发AMD加进展为晚期AMD(地图样萎缩、新生血管膜、视网膜色素上皮脱离或盘状瘢痕)的复合终点,基于自我报告并经医疗记录核实。
主要发现
- 参与者平均(SD)年龄为72.1(6.6)岁,12666名参与者(59.1%)为女性。
- 在中位(IQR)3.6(3.2-4.2)年的治疗和随访期间,344名参与者(1.6%)发生确诊AMD事件(316例新发AMD,28例进展为晚期AMD)。
- 主要复合终点在可可提取物组有159例(1.5%),安慰剂组有185例(1.7%)(HR 0.87,95%CI 0.71-1.08,P=0.21)。
- 因存在非比例风险证据(P=0.048),分别拟合Cox模型显示,治疗前2年可可提取物组风险降低23%(HR 0.77,95%CI 0.59-1.01),治疗超过2年无额外获益(HR 1.06,95%CI 0.76-1.50)。
- 次要试验结局(新发视力显著性AMD和晚期AMD)观察到类似的时间依赖性发现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出不能排除试验早期可能的适度治疗效果,需进一步研究以明确可可提取物是否有助于降低AMD风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Abnormalities of choroidal blood flow in the eye are associated with occurrence of age-related macular degeneration (AMD). Cocoa flavanols show beneficial effects on vascular risk factors in small and short-term trials and may help reduce AMD risk. OBJECTIVE: To examine whether daily supplementation with cocoa extract, a source of flavanols, prevents the development or progression of AMD. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified ancillary study of the COSMOS (COcoa Supplement and Multivitamins Outcomes Study) trial, a double-blind, placebo-controlled, 2 × 2 factorial randomized clinical trial of a cocoa extract supplement and a multivitamin supplement in the prevention of cardiovascular disease and cancer among 21 442 US adults, including 12 666 women aged 65 years and older and 8776 men aged 60 years and older. The intervention phase was performed from June 2015 through December 2020; data analysis was completed in August 2024. INTERVENTION: Cocoa extract supplement (500 mg/day cocoa flavanols, including 80 mg (-)-epicatechin) or placebo. MAIN OUTCOMES AND MEASURES: The primary end point was a composite of incident cases of AMD plus cases of progression to advanced AMD (geographic atrophy, neovascular membrane, retinal pigment epithelium detachment, or disciform scar) among participants with AMD at baseline, based on self-report confirmed by medical record review. RESULTS: Mean (SD) participant age was 72.1 (6.6) years, and 12 666 participants (59.1%) were female. During a median (IQR) period of 3.6 (3.2-4.2) years of treatment and follow-up, 344 participants (1.6%) experienced a confirmed AMD event (316 incident AMD, 28 progression to advanced AMD). For the primary composite end point, there were 159 cases (1.5%) in the cocoa extract group and 185 cases (1.7%) in the placebo group (hazard ratio [HR], 0.87; 95% CI, 0.71-1.08; P = .21). Separate Cox models fitted because of evidence of nonproportional hazards (P = .048) indicated a 23% decreased risk in the cocoa extract group during the first 2 years of treatment (HR, 0.77; 95% CI, 0.59-1.01), with no added benefit for treatment beyond 2 years (HR, 1.06; 95% CI, 0.76-1.50). Similar time-dependent findings were observed for the secondary trial outcomes of incident visually significant AMD and advanced AMD. CONCLUSIONS AND RELEVANCE: In this ancillary study of the COSMOS randomized clinical trial, cocoa extract supplementation for a median period of 3.6 years among older women and men had no effect overall on occurrence of AMD. However, a possible modest treatment effect early in the trial could not be ruled out, which warrants further investigation to clarify whether cocoa extract may help reduce AMD risk. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03205202.
引用
- Christen WG, Rist PM, Moorthy MV, et al. Cocoa Flavanol Supplementation and Risk of Age-Related Macular Degeneration: An Ancillary Study of the COSMOS Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 40146119. doi:10.1001/jamaophthalmol.2025.0353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。